This Week – March 10, 2018

This Week in Washington, D.C.

  • Call to Action: Urge your representatives to support the “Removing Barriers to Colorectal Cancer Screening Act” (S. 479; HR 1017)!
  • MIPS for all practice sizes: ACG advocating on behalf small and large GI practices
  • ACG Co-hosting Meeting with FDA: GREAT 5 for Pediatric Irritable Bowel Syndrome and Pediatric Functional Constipation

From ACG Legislative and Public Policy Council Chair, Whitfield L. Knapple, MD, FACG

MIPS for all practice sizes: ACG advocating on behalf small and large GI practices

MIPS and Larger Group Practices: Are larger groups unfairly treated in MIPS Quality Category?  What is ACG doing for you?

MACRA provides that the Centers for Medicare and Medicaid Services (CMS) may use global measures, such as global outcome measures, and population-based measures, for purposes of the quality performance category—and CMS is choosing to use this authority for group practices of 16 or more.  This will be included in the providers’ overall Quality score.  Practices do not actually report data.  Instead, CMS will calculate an “all cause hospital readmissions” population-based measure based on Medicare claims data.

For CY 2018, CMS states that the maximum quality performance score will continue to be 60 points for solo practitioners and groups of 15 or fewer clinicians (6 submitted measures x 10 points =60).  For group practices of 16 or more MIPS-eligible clinicians (not just physicians), this increases to 70 points.  CMS will also calculate an “all-cause hospital readmissions” population measure for your MIPS Quality score. The methodology:

  • 10 points for each of the 6 measures reported and 10 points for 1 population measure for groups of 16 or more.

What is this “population measure” that will impact the score of ACG members in larger group practices? What is ACG doing for solo and small practices? Click here to read the full blog.


Call to Action:
Urge your representatives to support the “Removing Barriers to Colorectal Cancer Screening Act” (S. 479; HR 1017)!

In honor of Colorectal Cancer Awareness month, take action now and urge your legislators to support the “Removing Barriers to Colorectal Cancer Screening Act!” This legislation fixes a Medicare coverage quirk by waiving Medicare beneficiary cost-sharing when screening colonoscopies turn therapeutic. Right now, Medicare only has the authority to waive the patient coinsurance for colonoscopies that remain a “screening.”

Colorectal cancer is the second leading cause of cancer deaths in the United States, with over 50,000 Americans expected to die from colorectal cancer this year alone. While this country is making progress against colorectal cancer incidence rates and mortality, more needs to be done to increase the use of screening tests by Medicare beneficiaries.

To help make an impact, your legislators need to hear from you directly, and the ACG website makes this process quick and simple. Use the link below to advocate your support.

Click here to take action now!


ACG Co-hosting Meeting with FDA

GREAT 5 for Pediatric Irritable Bowel Syndrome and Pediatric Functional Constipation

The ACG, American Gastroenterological Association (AGA), North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and FDA will be cosponsoring a public workshop in Silver Spring, Maryland on March 28, 2018, titled the Gastroenterology Regulatory Endpoints and the Advancement of Therapeutics, or GREAT 5.

The focus of this public workshop is Pediatric Irritable Bowel Syndrome and Pediatric Functional Constipation. The co-sponsored workshop will facilitate the ongoing dialogue among relevant parties on issues related to these pressing topics.

On-site registration will not be available.

Register here.

Click here for more information.